Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial | Zendy

Anne Derache | Zendy; Collins Iwuji | Zendy; Kathy Baisley | Zendy; Siva Danaviah | Zendy; AnneGeneviève Marcelin | Zendy; Vincent Cálvez | Zendy; Túlio de Oliveira | Zendy; François Dabis | Zendy; Kholoud Porter | Zendy; Deenan Pillay | Zendy

Open Access

Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial

Author(s) -

Anne Derache,

Collins Iwuji,

Kathy Baisley,

Siva Danaviah,

AnneGeneviève Marcelin,

Vincent Cálvez,

Túlio de Oliveira,

François Dabis,

Kholoud Porter,

Deenan Pillay

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy881

Subject(s) - efavirenz , nevirapine , medicine , emtricitabine , drug resistance , virology , hiv drug resistance , human immunodeficiency virus (hiv) , sida , drug , immunology , viral disease , antiretroviral therapy , pharmacology , viral load , microbiology and biotechnology , biology

Previous studies in human immunodeficiency virus (HIV)-positive individuals on thymidine analogue backbone antiretroviral therapy (ART) with either nevirapine or efavirenz have suggested poorer virological outcomes in the presence of pretreatment drug resistance (PDR). We assessed the impact of PDR on virological suppression (VS; <50 copies/mL) in individuals prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal within a treatment-as-prevention trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research